UK open data stance: bold or brash?

A UK proposal to make anonymous patient data available for pharma company research elicited cheers and jeers.

Part of a package of reforms unveiled by prime minister David Cameron last month, the proposal was intended to integrate medical research more closely with the NHS and biopharma.

Such drugmakers as Glaxo­SmithKline, as well as academics, hailed Cameron's plan. With privacy safeguards, “access to real data on patient treatment…could help to cut drug development costs and spur rapid innovation,” wrote the Financial Times in an op-ed.

However, medical societies and others warned that data could still include age profiles and post codes, which can be used to trace identities. “We are concerned that elements of the government's proposals could, if implemented, undermine patient confidentiality,” said the British Medical Association in a statement.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.